Table 2 What will change in 5 years? This table presents interviewees’ answers to the following question: “what do you think will change in five years?”
From: Clinical exome sequencing in France and Quebec: what are the challenges? What does the future hold?
France | Quebec | ||
|---|---|---|---|
Cancer | Principal Investigator | We will know more on the biology of cancers. | Genomics will be integrated in clinical practice, with a hybrid clinical and research mission. |
Clinician | We will have a standardized data analysis process. | WES will be approved for use in the clinic, and more will be understood about the biology of cancer. | |
Bioinformatician | Technology will be available across the territory. | WES and transcriptome will be used in the clinic, and all patients will be sequenced. | |
Head of biochemistry lab | Technology will be stable and costs will go down | ||
Rare Diseases | Principal Investigator | WGS will be used instead of WES, and used in rare diseases, cancers and common diseases. | Only one genetic test will be used, WGS, as long as it becomes cheaper than WES and targeted tests. |
Clinician | Genomics will be used for rare diseases, cancers and common diseases. | WES will be a formal clinical test offered with the appropriate resources, and will be applied in more diseases. | |
Researcher | WES will be implemented in the clinic, and WGS will be in the process of evaluation for the clinic. | ||
Bioinformatician | WGS will be used in the clinic. | The process of sequencing and analysis will be standardized throughout the province. | |